Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead - LARVOL DELTA

Hepatitis C Virus (HCV) Recurrence and Death After Viral Clearance in an HCV-Viremic Donor to HCV-Negative Kidney Recipient. (PubMed, Kidney Med) - "Sofosbuvir/velpatasvir was reinitiated with a plan to transition to sofosbuvir/velpatasvir/voxilaprevir...Fatal recurrence is rare in HCV NAT+/- kidney transplant recipients after completion of DAA regimen. HCV recurrence should be considered with abnormal liver chemistries in the absence of alternative explanations."

Journal • Diabetes • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Liver Failure • Metabolic Disorders • Solid Organ Transplantation • Transplantation • Type 2 Diabetes Mellitus

Sofosbuvir/Velpatasvir/Voxilaprevir Versus Sofosbuvir/Velpatasvir Plus Ribavirin in Patients With Hepatitis C Virus Genotype 3b and Compensated Cirrhosis: A Multicentre Randomized Controlled Trial. (PubMed, J Med Virol) - P4 | "Both regimens were well tolerated, with one serious adverse event in arm A. Compared to sofosbuvir/velpatasvir plus ribavirin, 12 weeks of sofosbuvir/velpatasvir/voxilaprevir treatment suggests a higher SVR proportion in DAA-naïve patients with HCV GT3b with compensated cirrhosis. Clinical Trial Number: NCT05467826."

Clinical • Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

Recent Advances in the Treatment of Chronic Hepatitis C (PubMed, Korean J Gastroenterol) - "Pan-genotypic regimens, including sofosbuvir/velpatasvir and glecaprevir/pibrentasvir, provide simplified, short-duration, and highly effective therapy. Sofosbuvir/velpatasvir/voxilaprevir is reserved for patients with prior DAA treatment failure...This review summarizes the current therapeutic updates for chronic hepatitis C, with a focus on pan-genotypic regimens, treatment duration, and strategies for special populations. Strengthening screening programs, optimizing retreatment, and expanding access are crucial for achieving the World Health Organization's goal of eliminating hepatitis C by 2030."

Journal • Review • Chronic Kidney Disease • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Liver Failure • Nephrology • Oncology • Renal Disease • Solid Tumor • Transplantation

THE MAJORITY OF PATIENTS WITH HEPATITIS C NOT ACHIEVING SVR CAN BE SUCCESSFULLY RETREATED WITH FIRST-LINE REGIMENS: RESULTS: FROM A MULTIDISCIPLINARY TEAM APPROACH TO GUIDE TREATMENT DECISIONS (AASLD 2025) - "A total of 263 retreatments were given, 176 (66.9%) 1st line (103 glecaprevir/pibrentasvir, 28 sofosbuvir/velpatasvir, 20 grazoprevir/elbasvir, 18 sofosbuvir/ledipasvir, 7 others) and 87 (33.1%) 2nd line (76 sofosbuvir/velpatasvir/voxilaprevir, 11 others).98 (37.2%) had documented risk factors for reinfection. An MDT approach to treatment failure, combined with resistance testing where available, allows for the majority of patients to be retreated with 1st line DAA regimen, with comparable rates of SVR to those treated with 2nd line regimens."

Clinical • Hepatitis C • Hepatology • Infectious Disease • Inflammation

IS SVR4 TESTING AN ACCEPTABLE ALTERNATIVE MEASURE OF HCV CURE IN RE-TREATED PATIENTS FOLLOWING DAA FAILURE? A SVR4/12 CONCORDANCE EVALUATION FROM THE POLARIS CLINICAL TRIALS (AASLD 2025) - "For this reason, we evaluate the SVR4/12 concordance of sofosbuvir/velpatasvir/voxilaprevir (S/V/V) in randomized clinical trials (RCTs)... HCV treatment with S/V/V can be infrequent in the real world and achieving SVR4 is highly predictive of HCV cure. This earlier time point to confirm HCV cure may be particularly important in persons at high-risk to be LTFU."

Clinical • Discordant • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation

RE-ENGAGEMENT TO RESCUE THERAPY WITH SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR IN HEPATITIS C AFTER DIRECT-ACTING ANTIVIRAL FAILURE (AASLD 2025) - "The introduction of SOF/VEL/VOX in Korea enabled the re-engagement of patients lost to follow-up after DAA failure and facilitated successful rescue therapy."

Hepatitis C • Hepatology • Infectious Disease • Inflammation

Efficacy of Sofosbuvir-Velpatasvir-Ribavirin Regimen for Retreatment of Chronic Hepatitis C in Patients With Prior DAA Failure: A Retrospective Study From a National Treatment Center. (PubMed, Int J Hepatol) - "In resource-limited settings where second-line DAAs (such as SOF/VEL/VOX) may be unavailable, optimizing first-line treatments is essential...Prior to retreatment, 27 patients had received a 12-week regimen of sofosbuvir and daclatasvir, while only three had been treated with the sofosbuvir-velpatasvir regimen... First-line DAAs are highly effective to treat naïve patients. In the absence of second-line options, retreatment with first-line DAAs (SOF/VEL plus ribavirin) is a viable alternative."

Journal • Retrospective data • Hepatitis C • Infectious Disease • Inflammation

Trends in Use of Direct-Acting Antivirals for Treatment of Hepatitis C Virus Infection in Australia 2016-2024. (PubMed, J Viral Hepat) - "Glecaprevir/pibrentasvir (pan-genotypic regimen) has maintained an average market share of 34% since its introduction in August 2018. Sofosbuvir/velpatasvir/voxilaprevir, listed on the PBS in April 2019, and used for salvage therapy, has had a smaller average market share of 4% since listing...Increasing retreatment rates underscore the need for ongoing monitoring and real-world evaluations. Future head-to-head comparisons may support optimal regimen selection."

Journal • Retrospective data • Fatigue • Hepatitis C • Infectious Disease • Inflammation

ACCESS+: Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy (clinicaltrials.gov) - P4 | N=576 | Not yet recruiting | Sponsor: ANRS, Emerging Infectious Diseases

New P4 trial • Hepatitis C • Infectious Disease • Inflammation

HCV Cure Rates in the THINKER-NEXT Trial of Transplanting Kidneys from HCV-Infected Donors into HCV-Negative Recipients (WTC 2025) - P2 | "Patients who failed S/V received Sofosbuvir/Velpatasvir/Voxilaprevir (S/V/V).* From 9/27/2021-1/5/2025, 201 HCV-negative patients were transplanted with a kidney from an HCV-RNA+ donor...196 received 12 weeks of S/V per protocol, while four patients underwent a modified protocol: a) S/V for 26 days due to the development of a perforated duodenal ulcer with prolonged NPO status (n=1); b) 8 weeks of Glecaprevir/Pibrentasvir (G/P) on post-KT day 3 due to initiation of amiodarone immediately post-transplant (n=1); and c) switch from S/V to G/P after initiating amiodarone within the first three weeks of KT (n=2)... In this multi-center trial of transplanting kidneys from HCV-RNA+ donors into HCV-negative recipients, we have demonstrated that with early initiation of HCV treatment within three days of KT, the cure rate with initial treatment is nearly 100%, and to date, all patients have been cured with first or second-line therapy. These data confirm that HCV cure rates..."

Late-breaking abstract • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Peptic Ulcer • Transplantation

Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye. (PubMed, Viruses) - "Mild adverse events included pruritus (2.1%, n = 3), fatigue (2.1%, n = 3), and nausea (1.4%, n = 2). The SOF/VEL/VOX combination is a highly effective and well-tolerated treatment option in treatment-naïve CHC patients, achieving an SVR12 rate of 97.5%."

Journal • Observational data • Real-world evidence • Retrospective data • Dermatology • Fatigue • Hepatitis C • Infectious Disease • Inflammation • Pruritus

Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study. (PubMed, Viruses) - "In this first prospective real-world study in South Korea, SOF/VEL-based regimens demonstrated excellent efficacy and safety, achieving 100% SVR12 in the per-protocol population, including patients with cirrhosis and prior treatment failure."

HEOR • Journal • Observational data • Real-world evidence • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

A global comparison of hepatitis B & C drug pricing. (PubMed, Ann Hepatol) - "HBV and HCV originator medications cost significantly more in the US compared to seven other major industrial countries. However, the introduction of HBV generic medications has lowered the cost of treatment for patients in the US. Future adoption of international reference pricing may help bridge remaining pricing disparities."

Journal • Pricing • Hepatitis B • Hepatitis C • Infectious Disease • Inflammation

RISK OF HEPATOCELLULAR CARCINOMA AFTER RECEIVING DIRECT ANTI-VIRAL AGENTS FOR THE TREATMENT OF HEPATITIS C VIRUS: MULTICENTRIC RETROSPECTIVE STUDY (DDW 2025) - "Subgroup analyses were performed for specific DAAAs combinations (Epclusa, Harvoni, Mavyret, Vosevi, and Zepatier). The findings highlight the importance of early DAAAs treatment in reducing the long-term complications of HCV. Further prospective studies with longer follow-up durations are warranted to confirm these associations."

Retrospective data • Hepatitis C • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Oncology • Solid Tumor

Hepatobiliary disorders and direct-acting antiviral (DAA) therapies: real-world evidence and insights from the EudraVigilance database. (PubMed, Expert Opin Drug Saf) - "Harvoni® showed a statistically significant lower frequency of reporting for the hepatobiliary disorders SOC when compared to Epclusa® and Vosevi® (ROR, 0.33; 95% CI [0.26 - 0.41], and ROR 0.31; 95% CI [0.19 - 0.48], respectively). Harvoni® showed a lower reporting frequency of hepatobiliary disorders and fewer drug ineffectiveness reports, suggesting it may be preferred over Epclusa® and Vosevi® in patients with preexisting liver or biliary conditions."

HEOR • Journal • Real-world evidence • Hepatology • Infectious Disease • Inflammation

Treatment Failure of Sofosbuvir/Velpatasvir for Donor-Derived Hepatitis C Genotype 3 (ISHLT 2025) - "He received induction immunosuppression with basiliximab, followed by tacrolimus, mycophenolate, and steroid taper. On PTD 295, he started a 24-week course of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX), with undetectable viral load as of PTD 407.Summary Organs from HCV-infected donors remain a viable option, but providers must consider predictors of treatment failure, particularly drug resistance, which is more common with genotype 3. Close monitoring for signs of failure and awareness of salvage therapy options are essential."

Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Pain • Solid Organ Transplantation

Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir for the Retreatment of Chronic Hepatitis C Patients with DAA Relapse (APASL 2025) - "The impact of gender, age, cirrhosis status, genotype, and the addition of ribavirin during treatment on HCV RNA clearance rates was assessed...Additionally, among the 58 relapsed patients, 22 patients had previously been treated with SOF/VEL, and 18 patients had been treated with Glecaprevir/Pibrentasvir... SOF/VEL/VOX is an effective and safe retreatment option for HCV patients who relapse after DAA therapy, demonstrating excellent virological response rates and good tolerability."

Clinical • Fibrosis • Gastrointestinal Disorder • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) retreatment achieves sustained virological response in direct-acting antiviral experienced patients with hepatitis C virus: a (APASL 2025) - "All participants were DAAs treatment experienced, including Sofosbuvir/Velpatesvir (SOF/VEL, 43.8%), Elbasvir/Grazoprevir (EBR/GZR, 25.0%), Coblopasvir/Sofosbuvir (CLP/SOF, 18.8%) and ledipasvir/Sofosbuvir (LDV/SOF, 12.3%). This real-world study confirms high efficacy and safety of SOF/VEL/VOX for the treatment of DAA-experienced chronic hepatitis C patients, even those with GT3b or cirrhosis in China. Treatment was well tolerated well, even in those received SOF/VEL/VOX plus ribavirin. Table and Figure:Figure 1.Table 1 Patient demographics and baseline characteristics"

Clinical • Fibrosis • Hematological Disorders • Hepatitis C • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Oncology • Solid Tumor

12-week treatment of sofosbuvir/velpatasvir plus ribavirin and sofosbuvir/velpatasvir/voxilaprevir for HCV patients with GT3b and compensated cirrhosis: a multicenter, randomized, open-label study in China (APASL 2025) - P4 | "Compared to SOF/VEL plus RBV treatment, 12 weeks of SOF/VEL/VOX treatment achieved a significantly higher SVR12 rate in DAAs treatment-naïve HCV patients with GT3b, compensated cirrhosis in China (NCT05467826). Table and Figure:Figure 1.Treatment response to SOF/VEL plus RBV and SOF/VEL/VOX. Figure 2.Characteristics of patients with virologic failure treated by SOF/VEL plus RBV."

Clinical • Fibrosis • Hepatitis C • Hepatology • Immunology • Inflammation

Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir as a salvage therapy for chronic hepatitis C patients with failed previous direct-acting antivirals treatment (APASL 2025) - "SOF/VEL/VOX was effective and well-tolerated for DAAs experienced CHC patients in China, including difficult-to-treat cases such as those with GT 3 and cirrhosis. Table and Figure:Figure 1. Figure 2."

Clinical • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Liver Cirrhosis • Oncology • Pain • Solid Tumor

Direct-Acting Antiviral Treatment Failure and Retreatment Strategies Following Hepatitis C-Positive Solid Organ Transplantation in Hepatitis C-Negative Recipients: A Multicenter Case Series. (PubMed, Transpl Infect Dis) - "Despite initial DAA failures, all HCV-negative SOT recipients achieved SVR following one or more courses of retreatment with DAAs."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Solid Organ Transplantation • Transplantation

Direct-acting antiviral treatment outcomes in people infected with endemic compared to epidemic hepatitis C virus subtypes in England. (PubMed, J Infect) - "This study provides further evidence that endemic HCV subtypes lead to sub-optimal DAA efficacy, which may impact global HCV elimination."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Analysis of the efficacy and safety profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of patients with chronic hepatitis C with failed DAAs therapy (PubMed, Zhonghua Gan Zang Bing Za Zhi) - "Objective: To explore the efficacy and safety profile of sofosbuvir/velpatasvir/voxilaprevir ± ribavirin (SOF/VEL/VOX±RBV) for salvage treatment of chronic hepatitis C patients who have failed direct-acting antivirals (DAAs). There were no serious adverse events, deaths, or interruptions of treatment due to adverse reactions. SOF/VEL/VOX is a safe and effective salvage treatment option for chronic hepatitis C patients who have failed DAAs therapy, and may be particularly beneficial to refractory populations infected with genotype 3 and combined with cirrhosis."

Journal • Retrospective data • Fatigue • Fibrosis • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Liver Cancer • Oncology • Pain • Solid Tumor

Integrating hepatitis C testing and treatment into routine HIV care in Cameroon is feasible. (PubMed, J Int AIDS Soc) - "Our study demonstrates the viability of integrating HCV testing and treatment into routine HIV care in Cameroon, yielding new HCV diagnoses and high cure rates. Cameroon can use this strategy to achieve HCV elimination goals, although improvements in testing uptake, diagnosis and treatment access, and laboratory capacity are needed."

Journal • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Introducing Sofosbuvir/Velpatasvir + Ribavirin as a Generic Retreatment Regimen for Hepatitis C: Evaluation of a Government Program in Rwanda. (PubMed, Clin Infect Dis) - "Sofosbuvir/velpatasvir/voxilaprevir is recommended for hepatitis C virus (HCV) retreatment in those who fail initial treatment but is unavailable in resource-limited settings. Of 231 participants, 174 were cured (75.3% intention-to-treat analysis). SOF/VEL + RBV may be considered for HCV retreatment in resource-limited settings."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation